Trial · NCT03675737
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) in All Participants | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 12.9 | 95% Confidence Interval 11.9 to 14.0 | Months | |
| Overall Survival (OS) in All Participants | Placebo + Chemotherapy (FP or CAPOX Regimen) | 11.5 | 95% Confidence Interval 10.6 to 12.1 | Months | |
| Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 13.0 | 95% Confidence Interval 11.6 to 14.2 | Months | |
| Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 | Placebo + Chemotherapy (FP or CAPOX Regimen) | 11.4 | 95% Confidence Interval 10.5 to 12.0 | Months | |
| Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10 | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 15.7 | 95% Confidence Interval 13.8 to 19.3 | Months | |
| Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10 | Placebo + Chemotherapy (FP or CAPOX Regimen) | 11.8 | 95% Confidence Interval 10.3 to 12.7 | Months | |
| Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 6.9 | 95% Confidence Interval 6.3 to 7.2 | Months | |
| Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants | Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 | 95% Confidence Interval 5.5 to 5.7 | Months | |
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 6.9 | 95% Confidence Interval 6.0 to 7.2 | Months | |
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 | Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 | 95% Confidence Interval 5.4 to 5.7 | Months | |
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10 | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 8.1 | 95% Confidence Interval 6.8 to 8.5 | Months | |
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10 | Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 | 95% Confidence Interval 5.4 to 6.7 | Months | |
| Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 51.3 | 95% Confidence Interval 47.7 to 54.8 | Percentage of Participants | |
| Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants | Placebo + Chemotherapy (FP or CAPOX Regimen) | 42.0 | 95% Confidence Interval 38.5 to 45.5 | Percentage of Participants | |
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 52.1 | 95% Confidence Interval 48.1 to 56.1 | Percentage of Participants | |
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 | Placebo + Chemotherapy (FP or CAPOX Regimen) | 42.6 | 95% Confidence Interval 38.7 to 46.6 | Percentage of Participants | |
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10 | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 60.6 | 95% Confidence Interval 54.6 to 66.3 | Percentage of Participants | |
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10 | Placebo + Chemotherapy (FP or CAPOX Regimen) | 43.0 | 95% Confidence Interval 37.1 to 49.1 | Percentage of Participants | |
| Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 8.0 | 95% Confidence Interval 7.0 to 9.7 | Months | |
| Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants | Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.7 | 95% Confidence Interval 5.5 to 6.9 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03675737/results